Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide

We have examined the involvement of the endocannabinoid system in the cardioprotection triggered by lipopolysaccharide (LPS). Rats were treated with saline or LPS (10 μg Kg−1). 24 h later, hearts were excised, retrogradely perfused, submitted to a low‐flow ischaemia (0.6 ml min−1) for 90 min and reperfused for 60 min. Some hearts were perfused with either SR 141716A (a cannabinoid CB1, receptor antagonist 1 μM), SR 144528 (a CB2 receptor anagonist μM), NNLA (3 μM) or sodium nitroprusside (1 μM) 5 min before ischaemia and during the ischaemic period. The cardioprotective effects of LPS treatment, in terms of infarction and functional recovery, were not altered by the perfusion of SR 141716A but abolished by both SR 144528 and NNLA. Finally, SR 144528 abolished the beneficial effects of SNP perfusion. Our results suggest an involvement of endocannabinoids, acting through the CB2 receptors, in the cardioprotection triggered by LPS against myocardial ischaemia. This could be attributed to a relationship between cannabinoids and NO.

[1]  G. Kunos,et al.  Platelet‐ and macrophage‐derived endogenous cannabinoids are involved in endotoxin‐induced hypotension , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  W. Campbell,et al.  Cannabinoid CB 1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca 2 1 channel current , 1999 .

[3]  S. Galiègue,et al.  Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. , 1995, European journal of biochemistry.

[4]  D. R. Compton,et al.  Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. , 1997, The Journal of pharmacology and experimental therapeutics.

[5]  R. Krebsbach,et al.  A sensitive endocannabinoid assay. The simultaneous analysis of N-acylethanolamines and 2-monoacylglycerols. , 2000, Chemistry and physics of lipids.

[6]  T. Saldeen,et al.  Reperfusion injury in the endotoxin‐treated rat heart: reevaluation of the role of nitric oxide , 1997, British journal of pharmacology.

[7]  P. Soubrié,et al.  SR141716A, a potent and selective antagonist of the brain cannabinoid receptor , 1994, FEBS letters.

[8]  G. Denhardt,et al.  Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. , 2000, The Journal of pharmacology and experimental therapeutics.

[9]  V. Lagente,et al.  Effects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice. , 1998, Life sciences.

[10]  G. Cabral,et al.  The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. , 1999, The Journal of pharmacology and experimental therapeutics.

[11]  P. Casellas,et al.  SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. , 1998, The Journal of pharmacology and experimental therapeutics.

[12]  G. Molderings,et al.  Presynaptic cannabinoid and imidazoline receptors in the human heart and their potential relationship , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

[13]  R. Pertwee,et al.  Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide. , 2000, European journal of pharmacology.

[14]  A. Makriyannis,et al.  Functional CB 1 cannabinoid receptors in human vascular endothelial cells , 2022 .

[15]  Y. Jeon,et al.  Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappa B/Rel activation. , 1996, Molecular pharmacology.

[16]  B. Szabo,et al.  Cannabinoids cause central sympathoexcitation and bradycardia in rabbits. , 2000, The Journal of pharmacology and experimental therapeutics.

[17]  Li Zhu,et al.  Δ-9-Tetrahydrocannabinol Inhibits Antitumor Immunity by a CB2 Receptor-Mediated, Cytokine-Dependent Pathway1 , 2000, The Journal of Immunology.

[18]  A. Harken,et al.  Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia-reperfusion injury of isolated rat hearts. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D. Piomelli,et al.  The endocannabinoid system as a target for therapeutic drugs. , 2000, Trends in pharmacological sciences.